Abstract
Background
Combined use of a retinoid and antimicrobial is recommended for acne, however, local tolerability issues may compromise patient adherence and treatment outcome.
Objectives
This multicentre, single-blinded controlled studywas designed to determine whether modified adapalene/benzoyl peroxide (A/BPO, Epiduo®, Galderma, France) regimens improve local tolerability during the first four weeks of treatment without impairing efficacy at Week 12.
Materials & Methods
In total, 120 subjects with mild-to-moderate acne received, during the first four weeks, A/BPO daily overnight (A/BPO-EN), A/BPO daily for three hours (A/BPO-3h), A/BPO daily overnight and a provided moisturizer lotion (A/BPO-moisturizer), or A/BPO every other night (A/BPO-EoN). Local tolerance assessments included signs and symptoms, global worst score (GWS), and total sum score (TSS). Efficacy was assessed based on lesion counts, investigator global assessment (IGA), and total lesion count reduction. Adherence, subject satisfaction, and overall safety were also assessed.
Results
The mean TSS was significantly reduced atWeek 1 with A/BPO-EoN vs. A/BPO-EN (p<0.05), and A/BPO-EoN led to the lowest GWS and a decrease in severity of stinging/burning and erythema (p<0.05). The A/BPO-moisturizer regimen prevented dryness and scaling compared with the A/BPO-EN regimen. The median decrease in lesions from baseline was similar in all groups: up to 67% for total, 72% for inflammatory, and 70% for non-inflammatory lesion counts. Adherence, IGA, patient satisfaction, and overall safety were excellent.
Conclusions
Modulating treatment regimens during the first four weeks improved local tolerability without impacting overall efficacy outcome after 12 weeks and may improve treatment adherence during the first weeks of therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Leyden JJ. New understandings of the pathogenesis of acne. J Acad Am Dermatol 1995; 32: S15–25.
Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne -update 2016 -short version. J Eur Acad Dermatol Venerol 2016; 30: 1261–8.
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Acad Am Dermatol 2016; 74: 945–73.e33.
Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Acad Am Dermatol 2003; 49: S1–37.
Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Acad Am Dermatol 2009; 60: S1–50.
Brogden RN, Goa KE. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53: 511–9.
Michel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br J Dermatol 1998; 139: 3–7.
Waugh J, Noble S, Scott LJ. Adapalene: a review of its use in the treatment of acne vulgaris. Drugs 2004; 64: 1465–78.
Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venerol 2001; 15: 51–5.
Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Acad Am Dermatol 2007; 57: 791–9.
Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 1180–9.
Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatol Treat 2011; 22: 197–205.
Gold LS, Tan J, Cruz-Santana A, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110–6.
Sittart JA, Costa A, Mulinari-Brenner F, Follador I, Azulay-Abulafia L, Castro LC. Multicenter study for efficacy and safety evaluation of a fixeddose combination gel with adapalen 0.1% and benzoyl peroxide 2.5% (Epiduo(R) for the treatment of acne vulgaris in Brazilian population. An Bras Dermatol 2015; 90: 1–16.
Gollnick HP, Funke G, Kors C, Titzmann T, Jostingmeyer P, Jackel A. Efficacy of adapalene/benzoyl peroxide combination in moderate inflammatory acne and its impact on patient adherence. J Dtsch Dermatol Ges 2015; 13: 557–65.
Gollnick HP, Friedrich M, Peschen M, et al. Effect of adapalene 0.1%/benzoyl peroxide 2.5% topical gel on quality of life and treatment adherence during long-term application in patients with predominantly moderate acne with or without concomitant medication -additional results from the non-interventional cohort study ELANG. J Eur Acad Dermatol Venereol 2015; 29: 23–9.
Yan AC, Treat JR. Beyond first-line treatment: management strategies for maintaining acne improvement and compliance. Cutis 2008; 82: 18–25.
Thiboutot D, Zaenglein A,Weiss J,Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Acad Am Dermatol 2008; 59: 792–800.
Dreno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 2010; 49: 448–56.
Del Rosso JQ. A qualitative and quantitative assessment of the application and use of topical acne medication by patients. Cutis 2005; 76: 109–13.
Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drug Dermatol 2006; 5: 985–90.
Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869–71.
Andres P, Pernin C, Poncet M. Adapalene-benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants. Cutis 2008; 81: 278–84.
Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drug Dermatol 2007; 6: 899–905.
Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379: 361–72.
Troielli PA, Asis B, Bermejo A, Bittar M, Cabrera H, Castro C. Community study of fixed-combination adapalene 0.1% and benzoyl peroxide 2.5% in acne. Skinmed 2010; 8: 17–22.
Callender VD, Preston N, Osborn C, Johnson L, Gottschalk RW. A meta-analysis to investigate the relation between fitzpatrick skin types and tolerability of adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol 2010; 3: 15–9.
Lott R, Taylor SL, O’Neill JL, Krowchuk DP, Feldman SR. Medication adherence among acne patients: a review. J Cosmet Dermatol 2010; 9: 160–6.
Kwon HH, Park SY, Yoon JY, Min S, Suh DH. Do tutorials on application method enhance adapalene-benzoyl peroxide combination gel tolerability in the treatment of acne? J Dermatol 2015; 42: 1058–65.
Tan J, Humphrey S, Vender R, et al. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014; 171: 1508–16.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tan, J., Bissonnette, R., Gratton, D. et al. The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study. Eur J Dermatol 28, 502–508 (2018). https://doi.org/10.1684/ejd.2018.3367
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2018.3367